MC-GGFG-AM-(10Me-11F-Camptothecin)

Cat. No.: HY-153360

CAS No.: 2873460-70-7

Molecular Formula: $C_{51}H_{56}FN_9O_{14}$

Molecular Weight: 1038.04

Target: Topoisomerase; Drug-Linker Conjugates for ADC

Pathway: Cell Cycle/DNA Damage; Antibody-drug Conjugate/ADC Related

Storage: -20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (96.34 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	0.9634 mL	4.8168 mL	9.6335 mL
	5 mM	0.1927 mL	0.9634 mL	1.9267 mL
	10 mM	0.0963 mL	0.4817 mL	0.9634 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells[1].

IC_{50} & Target

Topoisomerase I

REFERENCES

[1]. Madera L, et al. ZW251, a novel glypican-3-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload[J]. Cancer Research, 2023, 83(7_Supplement): 2658-2658.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA